Review



recombinant human nt3 rhnt3  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    R&D Systems recombinant human nt3 rhnt3
    Physicochemical characterization of PEGylated <t>NT3-BDNF</t> nanoparticles over 28 days (40 320 min) after formulation. ( A ) Loading efficiency of BDNF (open circles) and NT3 (filled circles) in PEGylated NT3–BDNF nanoparticles, determined by ELISA. ( B ) Representative TEM image of PEGylated NT3–BDNF nanoparticles deposited 24 h after formulation (magnification 50,000x; scale bar is 100 nm), showing a dispersed morphology maintained throughout the 28-day period. ( C ) Time-dependent changes in the hydrodynamic diameter ( d H ) of PEGylated NT3–BDNF nanoparticles measured by MADLS. The peak intensity data (open and filled points) correspond to the same nanoparticle population and reveal a bimodal size distribution, reflecting both smaller and larger particle fractions.The d H values were calculated from the Stokes–Einstein equation at pH 7.4 and ionic strength 0.15 M (293 K). Individual points indicate nanoparticle diameter distributions obtained from eight independent samples. ( D )Zeta potential (ζ) of the nanoparticles measured in PBS buffer and calculated using Henry’s equation at an ionic strength of 0.15 M. Dashed lines serve as visual guides. All syntheses were performed in six replicates, and error bars represent mean ± standard deviation (SD).
    Recombinant Human Nt3 Rhnt3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 216 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nt3+rhnt3/Recombinant+Human+BDNF+Protein/pmc13046777-334-21-26
    Average 96 stars, based on 216 article reviews
    recombinant human nt3 rhnt3 - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "Safety and biodistribution of intrathecal administration of mesenchymal stem cells (MSCs) and neurotrophin-releasing nanoparticles in a porcine CSF-guided delivery model for amyotrophic lateral sclerosis (ALS) drug discovery"

    Article Title: Safety and biodistribution of intrathecal administration of mesenchymal stem cells (MSCs) and neurotrophin-releasing nanoparticles in a porcine CSF-guided delivery model for amyotrophic lateral sclerosis (ALS) drug discovery

    Journal: Scientific Reports

    doi: 10.1038/s41598-026-40196-0

    Physicochemical characterization of PEGylated NT3-BDNF nanoparticles over 28 days (40 320 min) after formulation. ( A ) Loading efficiency of BDNF (open circles) and NT3 (filled circles) in PEGylated NT3–BDNF nanoparticles, determined by ELISA. ( B ) Representative TEM image of PEGylated NT3–BDNF nanoparticles deposited 24 h after formulation (magnification 50,000x; scale bar is 100 nm), showing a dispersed morphology maintained throughout the 28-day period. ( C ) Time-dependent changes in the hydrodynamic diameter ( d H ) of PEGylated NT3–BDNF nanoparticles measured by MADLS. The peak intensity data (open and filled points) correspond to the same nanoparticle population and reveal a bimodal size distribution, reflecting both smaller and larger particle fractions.The d H values were calculated from the Stokes–Einstein equation at pH 7.4 and ionic strength 0.15 M (293 K). Individual points indicate nanoparticle diameter distributions obtained from eight independent samples. ( D )Zeta potential (ζ) of the nanoparticles measured in PBS buffer and calculated using Henry’s equation at an ionic strength of 0.15 M. Dashed lines serve as visual guides. All syntheses were performed in six replicates, and error bars represent mean ± standard deviation (SD).
    Figure Legend Snippet: Physicochemical characterization of PEGylated NT3-BDNF nanoparticles over 28 days (40 320 min) after formulation. ( A ) Loading efficiency of BDNF (open circles) and NT3 (filled circles) in PEGylated NT3–BDNF nanoparticles, determined by ELISA. ( B ) Representative TEM image of PEGylated NT3–BDNF nanoparticles deposited 24 h after formulation (magnification 50,000x; scale bar is 100 nm), showing a dispersed morphology maintained throughout the 28-day period. ( C ) Time-dependent changes in the hydrodynamic diameter ( d H ) of PEGylated NT3–BDNF nanoparticles measured by MADLS. The peak intensity data (open and filled points) correspond to the same nanoparticle population and reveal a bimodal size distribution, reflecting both smaller and larger particle fractions.The d H values were calculated from the Stokes–Einstein equation at pH 7.4 and ionic strength 0.15 M (293 K). Individual points indicate nanoparticle diameter distributions obtained from eight independent samples. ( D )Zeta potential (ζ) of the nanoparticles measured in PBS buffer and calculated using Henry’s equation at an ionic strength of 0.15 M. Dashed lines serve as visual guides. All syntheses were performed in six replicates, and error bars represent mean ± standard deviation (SD).

    Techniques Used: Formulation, Enzyme-linked Immunosorbent Assay, Zeta Potential Analyzer, Standard Deviation

    Related Articles

    Recombinant:

    Article Title: The Impact of Protein Corona Formation on PEGylated NT3- BDNF Nanoparticles - Distribution, Protein Release, and Cytotoxicity in Human Retinal Pigmented Epithelial Cell Model
    Article Snippet: .. BDNF and NT-3: In our studies, un ltered stock solutions of carrier-free recombinant human BDNF (rhBDNF) (248-BDB250/CF, R&D Systems, Canada), as well as carrier-free recombinant human NT3 (rhNT3) (248-N4-250/CF, R&D Systems) of known concentrations (typically 250 mgL-1), were prepared in the phosphate buffered saline (PBS) pH 7.4 +/- 0.2, 0.15M (Biomed, Lublin, Poland), and stored no longer than 2 months at the temperature − 20 ̊C. rhBDNF and rhNT3 collectively, hereinafter referred to as neurotrophins (NTs). ..

    Article Title: Safety and biodistribution of intrathecal administration of mesenchymal stem cells (MSCs) and neurotrophin-releasing nanoparticles in a porcine CSF-guided delivery model for amyotrophic lateral sclerosis (ALS) drug discovery
    Article Snippet: .. Unfiltered stock solutions (typically 250 mg L-1) of carrier-free recombinant human BDNF (rhBDNF) (248-N4-250/CF; R&D Systems, Canada), as well as carrier-free recombinant human NT3 (rhNT3) (248-BDB-250/CF; R&D Systems), were prepared by dissolving lyophilized of known concentrations in phosphate-buffered saline (PBS) (pH 7.4 ± 0.2, 0.15 M; Biomed, Lublin, Poland) and storing them for no longer than 2 months at −20 °C. ..

    Article Title: The Impact of Serum Protein Adsorption on PEGylated NT3-BDNF Nanoparticles-Distribution, Protein Release, and Cytotoxicity in a Human Retinal Pigmented Epithelial Cell Model.
    Article Snippet: .. BDNF and NT-3 In our studies, unfiltered stock solutions of carrier-free recombinant human BDNF (rhBDNF) (248-BDB-250/CF, R&D Systems, Minneapolis, MN, USA) as well as carrier-free recombinant human NT3 (rhNT3) (248-N4-250/CF, R&D Systems), of known concentrations (typically 250 mg L−1), were prepared in phosphate buffered saline (PBS) pH 7.4 ± 0.2, 0.15 M (Biomed, Lublin, Poland) and stored for no longer than 2 months at a temperature of −20 ◦C. rhBDNF and rhNT3 are hereinafter collectively referred to as neurotrophins (NTs). ..

    Article Title: In vitro and in vivo characterization of human serum albumin-based PEGylated nanoparticles for BDNF and NT3 codelivery.
    Article Snippet: .. Unfiltered stock solutions (typically 250 mg L− 1) of carrier-free recombinant human BDNF (rhBDNF) (248-N4-250/CF; R&D Systems, Canada), as well as carrier-free recombinant human NT3 (rhNT3) (248- BDB-250/CF; R&D Systems), were prepared by dissolving lyophilizates of known concentrations in phosphate-buffered saline (PBS) (pH 7.4 ± 0.2, 0.15 M; Biomed, Lublin, Poland) and storing them for no longer than 2 months at − 20 ◦C. ..

    Article Title: Safety and biodistribution of intrathecal administration of mesenchymal stem cells (MSCs) and neurotrophin-releasing nanoparticles in a porcine CSF-guided delivery model for amyotrophic lateral sclerosis (ALS) drug discovery.
    Article Snippet: .. BDNF and NT3 Unfiltered stock solutions (typically 250 mg L-1) of carrier-free recombinant human BDNF (rhBDNF) (248-N4-250/CF; R&D Systems, Canada), as well as carrier-free recombinant human NT3 (rhNT3) (248- BDB-250/CF; R&D Systems), were prepared by dissolving lyophilized of known concentrations in phosphate-buffered saline (PBS) (pH 7.4 ± 0.2, 0.15 M; Biomed, Lublin, Poland) and storing them for no longer than 2 months at -20 °C. ..

    Saline:

    Article Title: The Impact of Protein Corona Formation on PEGylated NT3- BDNF Nanoparticles - Distribution, Protein Release, and Cytotoxicity in Human Retinal Pigmented Epithelial Cell Model
    Article Snippet: .. BDNF and NT-3: In our studies, un ltered stock solutions of carrier-free recombinant human BDNF (rhBDNF) (248-BDB250/CF, R&D Systems, Canada), as well as carrier-free recombinant human NT3 (rhNT3) (248-N4-250/CF, R&D Systems) of known concentrations (typically 250 mgL-1), were prepared in the phosphate buffered saline (PBS) pH 7.4 +/- 0.2, 0.15M (Biomed, Lublin, Poland), and stored no longer than 2 months at the temperature − 20 ̊C. rhBDNF and rhNT3 collectively, hereinafter referred to as neurotrophins (NTs). ..

    Article Title: Safety and biodistribution of intrathecal administration of mesenchymal stem cells (MSCs) and neurotrophin-releasing nanoparticles in a porcine CSF-guided delivery model for amyotrophic lateral sclerosis (ALS) drug discovery
    Article Snippet: .. Unfiltered stock solutions (typically 250 mg L-1) of carrier-free recombinant human BDNF (rhBDNF) (248-N4-250/CF; R&D Systems, Canada), as well as carrier-free recombinant human NT3 (rhNT3) (248-BDB-250/CF; R&D Systems), were prepared by dissolving lyophilized of known concentrations in phosphate-buffered saline (PBS) (pH 7.4 ± 0.2, 0.15 M; Biomed, Lublin, Poland) and storing them for no longer than 2 months at −20 °C. ..

    Article Title: The Impact of Serum Protein Adsorption on PEGylated NT3-BDNF Nanoparticles-Distribution, Protein Release, and Cytotoxicity in a Human Retinal Pigmented Epithelial Cell Model.
    Article Snippet: .. BDNF and NT-3 In our studies, unfiltered stock solutions of carrier-free recombinant human BDNF (rhBDNF) (248-BDB-250/CF, R&D Systems, Minneapolis, MN, USA) as well as carrier-free recombinant human NT3 (rhNT3) (248-N4-250/CF, R&D Systems), of known concentrations (typically 250 mg L−1), were prepared in phosphate buffered saline (PBS) pH 7.4 ± 0.2, 0.15 M (Biomed, Lublin, Poland) and stored for no longer than 2 months at a temperature of −20 ◦C. rhBDNF and rhNT3 are hereinafter collectively referred to as neurotrophins (NTs). ..

    Article Title: In vitro and in vivo characterization of human serum albumin-based PEGylated nanoparticles for BDNF and NT3 codelivery.
    Article Snippet: .. Unfiltered stock solutions (typically 250 mg L− 1) of carrier-free recombinant human BDNF (rhBDNF) (248-N4-250/CF; R&D Systems, Canada), as well as carrier-free recombinant human NT3 (rhNT3) (248- BDB-250/CF; R&D Systems), were prepared by dissolving lyophilizates of known concentrations in phosphate-buffered saline (PBS) (pH 7.4 ± 0.2, 0.15 M; Biomed, Lublin, Poland) and storing them for no longer than 2 months at − 20 ◦C. ..

    Article Title: Safety and biodistribution of intrathecal administration of mesenchymal stem cells (MSCs) and neurotrophin-releasing nanoparticles in a porcine CSF-guided delivery model for amyotrophic lateral sclerosis (ALS) drug discovery.
    Article Snippet: .. BDNF and NT3 Unfiltered stock solutions (typically 250 mg L-1) of carrier-free recombinant human BDNF (rhBDNF) (248-N4-250/CF; R&D Systems, Canada), as well as carrier-free recombinant human NT3 (rhNT3) (248- BDB-250/CF; R&D Systems), were prepared by dissolving lyophilized of known concentrations in phosphate-buffered saline (PBS) (pH 7.4 ± 0.2, 0.15 M; Biomed, Lublin, Poland) and storing them for no longer than 2 months at -20 °C. ..



    Similar Products

    recombinant human nt3 rhnt3  (R&D Systems)
    96
    R&D Systems recombinant human nt3 rhnt3
    Physicochemical characterization of PEGylated <t>NT3-BDNF</t> nanoparticles over 28 days (40 320 min) after formulation. ( A ) Loading efficiency of BDNF (open circles) and NT3 (filled circles) in PEGylated NT3–BDNF nanoparticles, determined by ELISA. ( B ) Representative TEM image of PEGylated NT3–BDNF nanoparticles deposited 24 h after formulation (magnification 50,000x; scale bar is 100 nm), showing a dispersed morphology maintained throughout the 28-day period. ( C ) Time-dependent changes in the hydrodynamic diameter ( d H ) of PEGylated NT3–BDNF nanoparticles measured by MADLS. The peak intensity data (open and filled points) correspond to the same nanoparticle population and reveal a bimodal size distribution, reflecting both smaller and larger particle fractions.The d H values were calculated from the Stokes–Einstein equation at pH 7.4 and ionic strength 0.15 M (293 K). Individual points indicate nanoparticle diameter distributions obtained from eight independent samples. ( D )Zeta potential (ζ) of the nanoparticles measured in PBS buffer and calculated using Henry’s equation at an ionic strength of 0.15 M. Dashed lines serve as visual guides. All syntheses were performed in six replicates, and error bars represent mean ± standard deviation (SD).
    Recombinant Human Nt3 Rhnt3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+nt3+rhnt3/Recombinant+Human+BDNF+Protein/pmc13046777-334-21-26
    Average 96 stars, based on 1 article reviews
    recombinant human nt3 rhnt3 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Physicochemical characterization of PEGylated NT3-BDNF nanoparticles over 28 days (40 320 min) after formulation. ( A ) Loading efficiency of BDNF (open circles) and NT3 (filled circles) in PEGylated NT3–BDNF nanoparticles, determined by ELISA. ( B ) Representative TEM image of PEGylated NT3–BDNF nanoparticles deposited 24 h after formulation (magnification 50,000x; scale bar is 100 nm), showing a dispersed morphology maintained throughout the 28-day period. ( C ) Time-dependent changes in the hydrodynamic diameter ( d H ) of PEGylated NT3–BDNF nanoparticles measured by MADLS. The peak intensity data (open and filled points) correspond to the same nanoparticle population and reveal a bimodal size distribution, reflecting both smaller and larger particle fractions.The d H values were calculated from the Stokes–Einstein equation at pH 7.4 and ionic strength 0.15 M (293 K). Individual points indicate nanoparticle diameter distributions obtained from eight independent samples. ( D )Zeta potential (ζ) of the nanoparticles measured in PBS buffer and calculated using Henry’s equation at an ionic strength of 0.15 M. Dashed lines serve as visual guides. All syntheses were performed in six replicates, and error bars represent mean ± standard deviation (SD).

    Journal: Scientific Reports

    Article Title: Safety and biodistribution of intrathecal administration of mesenchymal stem cells (MSCs) and neurotrophin-releasing nanoparticles in a porcine CSF-guided delivery model for amyotrophic lateral sclerosis (ALS) drug discovery

    doi: 10.1038/s41598-026-40196-0

    Figure Lengend Snippet: Physicochemical characterization of PEGylated NT3-BDNF nanoparticles over 28 days (40 320 min) after formulation. ( A ) Loading efficiency of BDNF (open circles) and NT3 (filled circles) in PEGylated NT3–BDNF nanoparticles, determined by ELISA. ( B ) Representative TEM image of PEGylated NT3–BDNF nanoparticles deposited 24 h after formulation (magnification 50,000x; scale bar is 100 nm), showing a dispersed morphology maintained throughout the 28-day period. ( C ) Time-dependent changes in the hydrodynamic diameter ( d H ) of PEGylated NT3–BDNF nanoparticles measured by MADLS. The peak intensity data (open and filled points) correspond to the same nanoparticle population and reveal a bimodal size distribution, reflecting both smaller and larger particle fractions.The d H values were calculated from the Stokes–Einstein equation at pH 7.4 and ionic strength 0.15 M (293 K). Individual points indicate nanoparticle diameter distributions obtained from eight independent samples. ( D )Zeta potential (ζ) of the nanoparticles measured in PBS buffer and calculated using Henry’s equation at an ionic strength of 0.15 M. Dashed lines serve as visual guides. All syntheses were performed in six replicates, and error bars represent mean ± standard deviation (SD).

    Article Snippet: Unfiltered stock solutions (typically 250 mg L-1) of carrier-free recombinant human BDNF (rhBDNF) (248-N4-250/CF; R&D Systems, Canada), as well as carrier-free recombinant human NT3 (rhNT3) (248-BDB-250/CF; R&D Systems), were prepared by dissolving lyophilized of known concentrations in phosphate-buffered saline (PBS) (pH 7.4 ± 0.2, 0.15 M; Biomed, Lublin, Poland) and storing them for no longer than 2 months at −20 °C.

    Techniques: Formulation, Enzyme-linked Immunosorbent Assay, Zeta Potential Analyzer, Standard Deviation